HIGHLIGHTS
- who: Philadelphia chromosome-positive acute and colleagues from the Peking University People's Hospital, Peking University Institute of Transplantation, Beijing, PR. China have published the research: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia, in the Journal: (JOURNAL)
- what: A study was designed to investigate the safety of imatinib and its efficacy in preventing hematological relapse and improving disease-free survival (DFS) when administered after allogeneic hematopoietic stem cell transplantation (allo-HCT). Twenty patients did not receive imatinib therapy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.